About Teleflex Incorporated
https://www.teleflex.comTeleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.
CEO
Liam J. Kelly
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1997-06-17 | Forward | 2:1 |
| 1991-06-17 | Forward | 3:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 222
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Morgan Stanley
Overweight
Wells Fargo
Equal Weight
Citizens Capital Markets
Market Perform
RBC Capital
Sector Perform
Mizuho
Neutral
Piper Sandler
Neutral
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:5.34M
Value:$550.01M
VANGUARD GROUP INC
Shares:4.8M
Value:$494.31M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:4.57M
Value:$470.84M
Summary
Showing Top 3 of 610
About Teleflex Incorporated
https://www.teleflex.comTeleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $913.02M ▲ | $481.34M ▲ | $-408.89M ▼ | -44.78% ▼ | $-9.24 ▼ | $-323.04M ▼ |
| Q2-2025 | $780.89M ▲ | $275.77M ▲ | $122.58M ▲ | 15.7% ▲ | $2.77 ▲ | $222.67M ▲ |
| Q1-2025 | $700.67M ▼ | $263.87M ▼ | $95M ▲ | 13.56% ▲ | $2.08 ▲ | $194.82M ▲ |
| Q4-2024 | $795.41M ▲ | $550.3M ▲ | $-136.66M ▼ | -17.18% ▼ | $-2.95 ▼ | $-36.33M ▼ |
| Q3-2024 | $764.38M | $280.86M | $111M | 14.52% | $2.38 | $220.25M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $354M ▲ | $7.87B ▲ | $4.05B ▲ | $3.82B ▼ |
| Q2-2025 | $253.7M ▼ | $7.38B ▲ | $3.13B ▲ | $4.24B ▲ |
| Q1-2025 | $284.12M ▼ | $7.16B ▲ | $3.07B ▲ | $4.1B ▼ |
| Q4-2024 | $290.19M ▲ | $7.1B ▼ | $2.82B ▼ | $4.28B ▼ |
| Q3-2024 | $243.24M | $7.49B | $3B | $4.48B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-408.89M ▼ | $107.63M ▲ | $-767.5M ▼ | $756.34M ▲ | $97.39M ▲ | $77.69M ▲ |
| Q2-2025 | $122.58M ▲ | $7.74M ▼ | $-30.49M ▼ | $-23.67M ▲ | $-33.56M ▼ | $-26.89M ▼ |
| Q1-2025 | $95M ▲ | $73.09M ▼ | $-28.79M ▼ | $-59.52M ▲ | $-10.17M ▼ | $43.08M ▼ |
| Q4-2024 | $-136.66M ▼ | $202.47M ▼ | $-23.09M ▼ | $-119.11M ▲ | $49.88M ▲ | $170.45M ▼ |
| Q3-2024 | $111M | $230.98M | $-21.23M | $-174.82M | $39.2M | $209.8M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Anesthesia | $100.00M ▲ | $90.00M ▼ | $100.00M ▲ | $100.00M ▲ |
 Interventional | $160.00M ▲ | $140.00M ▼ | $170.00M ▲ | $270.00M ▲ |
 Interventional Urology | $80.00M ▲ | $70.00M ▼ | $80.00M ▲ | $70.00M ▼ |
 Other | $60.00M ▲ | $50.00M ▼ | $60.00M ▲ | $80.00M ▲ |
 Surgical | $120.00M ▲ | $110.00M ▼ | $110.00M ▲ | $120.00M ▲ |
 Vascular Access | $190.00M ▲ | $180.00M ▼ | $190.00M ▲ | $190.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Americas Segment | $620.00M ▲ | $480.00M ▼ | $530.00M ▲ | $560.00M ▲ |
 Asia | $60.00M ▲ | $70.00M ▲ | $90.00M ▲ | $120.00M ▲ |
 EMEA | $250.00M ▲ | $150.00M ▼ | $170.00M ▲ | $230.00M ▲ |
CEO
Liam J. Kelly
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1997-06-17 | Forward | 2:1 |
| 1991-06-17 | Forward | 3:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 222
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Morgan Stanley
Overweight
Wells Fargo
Equal Weight
Citizens Capital Markets
Market Perform
RBC Capital
Sector Perform
Mizuho
Neutral
Piper Sandler
Neutral
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:5.34M
Value:$550.01M
VANGUARD GROUP INC
Shares:4.8M
Value:$494.31M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:4.57M
Value:$470.84M
Summary
Showing Top 3 of 610